Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and ...

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.62%, ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.92% to $485.89 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to ...

Vertex Pharmaceuticals continues to develop therapies where there is a need. Veeva Systems has a long runway for growth in its niche of the cloud market. Equity markets have been seesawing for the ...

BOSTON, April 11, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

In a series of recent legal challenges initiated by the pharmaceutical industry against the US Department of Health and Human Services Office of ...

Vertex Pharmaceuticals is a leading drugmaker that develops therapies in areas with high unmet needs. That's not a bad strategy. Despite significant advances and innovations in medicine ...

Meta Platforms will remain an advertising magnet and an AI leader. Vertex Pharmaceuticals has multiple growth drivers with potentially more on the way. Yo-yos are fun for kids. But yo-yo stock ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...